dc.contributor.author
Santacruz Escudero, José Manuel
dc.contributor.author
Beltrán, Jonathan
dc.contributor.author
Palacios, Álvaro
dc.contributor.author
Chimbí, Claudia Marcela
dc.contributor.author
Matallana, Diana
dc.contributor.author
Reyes, Pablo
dc.contributor.author
Pérez Solà, Víctor
dc.contributor.author
Santamaría-García, Hernando
dc.date.accessioned
2024-11-04T01:16:49Z
dc.date.available
2024-11-04T01:16:49Z
dc.identifier
https://ddd.uab.cat/record/253327
dc.identifier
urn:10.3389/fnagi.2019.00176
dc.identifier
urn:oai:ddd.uab.cat:253327
dc.identifier
urn:pmcid:PMC6668630
dc.identifier
urn:pmc-uid:6668630
dc.identifier
urn:pmid:31396074
dc.identifier
urn:oai:pubmedcentral.nih.gov:6668630
dc.identifier
urn:oai:egreta.uab.cat:publications/bbc8edd5-b522-44d1-b0a2-6c280edc86cb
dc.identifier.uri
https://hdl.handle.net/2072/459458
dc.description.abstract
Background : To study the extent to which neuropsychiatric symptoms (NPS) influence the cognitive and functional decline in frontotemporal degeneration (FTD) and Alzheimer's disease (AD). Methods : We assessed the progression of NPS and their influence on cognitive and functional progression in a group of FTD (n = 36) and AD patients (n = 47) at two different stages of the disease (2.5 years). A standardized scale was used to assess NPS-the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD)-which tracks different symptoms including depression, psychotic symptoms, as well as sleep and conduct problems. In addition, in a subsample of patients (AD n = 14 and FTD n = 14), we analyzed another group of NPS by using the Neuropsychiatric Inventory (NPI). Cognitive declines were tracked by using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while functionality was tracked by using the Lawton scale and the Barthel Index. Results : The presence of NPS impacts cognitive and functional decline in both groups of patients 2.5 years after disease onset. However, we observed a dissociable profile of the affectation of NPS in each group. In the AD group, results indicate that the progression of depressive symptoms and sleep problems predict cognitive and functional decline. In contrast, the progression of a mixed group of NPS, including conduct problems and delusions, predicts cognitive and functional decline in FTD. Conclusion : The presence of NPS has a critical impact on the prediction of cognitive decline in FTD and AD patients after 2.5 years of disease progression. Our results demonstrate the importance of assessing different types of NPS in neurodegenerative disorders which, in turn, predict disease progression. Future studies should assess the role of NPS in predicting different neurocognitive pathways and in neurodegeneration.
dc.format
application/pdf
dc.relation
Frontiers in aging neuroscience ; Vol. 11 (july 2019)
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.subject
Frontotemporal dementia
dc.subject
Alzheimer's disease
dc.subject
Behavioral disturbances
dc.subject
Cohort studies
dc.subject
Assessment of cognitive disorders/dementia
dc.title
Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study